Ntla.info
Web12 nov. 2024 · Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the... Web6 apr. 2024 · Further, Intellia Therapeutics Inc. (NTLA) has a beta value of 1.87, and an average true range (ATR) of 2.11. Analysts have given the company’s stock an average 52-week price target of $94.69, forecast between a low of $39.00 and high of $168.00. Looking at the price targets, the low is -8.97% off current price level while to achieve the ...
Ntla.info
Did you know?
WebQuarterly Numbers. Actuals. Estimates. NTLA will report Q1 2024 earnings on 05/04/2024. Q1 2024. Q2 2024. Q3 2024. Web8 apr. 2024 · NTLA Stock Overview Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. About the company Rewards Revenue is forecast to grow 48.92% per year Risk Analysis Currently unprofitable and not forecast to become profitable over the next 3 years Shareholders have been diluted in the past year
Web22 uur geleden · See the latest Intellia Therapeutics Inc stock price (NASDAQ:NTLA), related news, valuation, dividends and more to help you make your investing decisions. Web22 uur geleden · NTLA’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Web16 mrt. 2024 · NTLA-2001 is a new CRISPR-Cas9–based in vivo gene-editing therapy, administered by intravenous infusion, that is intended to edit TTR in hepatocytes, leading to a decrease in the production of... Web1 dag geleden · View Intellia Therapeutics, Inc NTLA investment & stock information. Get the latest Intellia Therapeutics, Inc NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
Web12 apr. 2024 · Intellia Therapeutics (NASDAQ:NTLA) has a recorded annual revenue of $52.12 million. How much profit does Intellia Therapeutics generate each year? Intellia Therapeutics (NASDAQ:NTLA) has a recorded net income of -$474.19 million. NTLA has generated -$6.18 earnings per share over the last four quarters.
WebIntellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in … taxi for disabled londonWeb22 uur geleden · The NTLA provides networking and training opportunities in the tax lien industry and credentialing to become a Certified Tax Lien Professional, CTLP®. For more information, please visit:... taxi forest hills nyWeb30 dec. 2024 · Dec 30, 2024. Editas Medicine, Inc. ( EDIT) and Intellia Therapeutics, Inc. ( NTLA) are two emerging gene editing companies that are focused on developing transformative genomic medicines to treat a range of serious diseases. EDIT develops a proprietary genome editing platform based on CRISPR technology. NTLA, develops vivo … taxi for covid patientsWeb5 nov. 2024 · Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. To fully realize the transformative potential of CRISPR-based technologies, Intellia is pursuing two primary approaches. the christmas truce videoWebNTLA Complete Intellia Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. the christmas village shopWeb7 uur geleden · Petros Pharmaceuticals stock is rising alongside heavy trading this morning.; That’s despite a lack of news concerning the company. PTPI’s penny stock status may explain today’s rally. taxi forbachWebParticipants had the opportunity to choose from 21 unique sessions including topics such as: Title Defects and Remedies, Tribal Airspace Rights, Contemporary Land Trusts, Fee-to-Trust Tribal Acquisitions to Federal Conveyance, Land or Real Property Codes, and Sustainable forestland managements. the christmas village movie cast